Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program

This publication has 12 references indexed in Scilit:

• Efficacy and Pharmacoeconomic Impact of Letermovir for CMV Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
  Transplantation and Cellular Therapy, 2019
• Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection
  American Journal of Transplantation, 2018
• Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir‐resistant cytomegalovirus syndrome (UL97 mutation)
  Transplant Infectious Disease, 2018
• Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
  New England Journal of Medicine, 2017
• Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients
  BMC Infectious Diseases, 2017
• Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring
  Transplantation and Cellular Therapy, 2017
• Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.
  Clinical Infectious Diseases, 2016
• Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status
  Clinical Microbiology and Infection, 2016
• Reprint of: Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies
  Transplantation and Cellular Therapy, 2015
• Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
  New England Journal of Medicine, 2014